Loading clinical trials...
Loading clinical trials...
A 24-month, Multi-center, Randomized, Open-label, Non-inferiority Study of Efficacy and Safety Comparing Two Exposures of Concentration-controlled Everolimus With Reduced Cyclosporine Versus 3.0 g Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Heart Transplant Recipients
Conditions
Interventions
everolimus
mycophenolate mofetil
+2 more
Locations
64
United States
UCLA Medical Center
Los Angeles, California, United States
California Pacific Medical Center
San Francisco, California, United States
Stanford U Sch, Falk Cardiovasular Research Ctr.
Stanford, California, United States
University of Florida Shands Hospital
Gainesville, Florida, United States
Emory University Hospital
Atlanta, Georgia, United States
Loyola Univerisity Medical School
Maywood, Illinois, United States
Start Date
January 1, 2006
Primary Completion Date
July 1, 2011
Completion Date
July 1, 2011
Last Updated
August 16, 2012
NCT00106925
NCT06532890
NCT07316829
NCT03719339
NCT06090799
NCT02102854
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions